Advanced search
Publication Cover
OncoTargets and Therapy Volume 10, 2017 - Issue
Submit an article Journal homepage
40
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib

Konstantinos Koutsoukos1 Hellenic Genito-Urinary Cancer Group;2 Oncology Unit, Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, GreeceCorrespondence[email protected]
,
Aristotelis Bamias1 Hellenic Genito-Urinary Cancer Group;2 Oncology Unit, Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece
,
Kimon Tzannis1 Hellenic Genito-Urinary Cancer Group
,
Marta Espinosa Montaño3 Medical Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
,
Vasiliki Bozionelou4 Department of Medical Oncology, University Hospital of Heraklion, Heraklion
,
Christos Christodoulou5 2nd Oncology Clinic, Metropolitan Hospital, Piraeus
,
Dimitra Stefanou6 1st Department of Medical Oncology, Saint Savvas Anticancer Hospital, Athens
,
Haralabos Kalofonos7 Division of Oncology, Department of Medicine, University Hospital, University of Patras Medical School, Patras
,
Ignacio Duran3 Medical Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
&
Konstantinos Papazisis1 Hellenic Genito-Urinary Cancer Group;8 Euromedica General Clinic, Thessaloniki, Greece
 show all
Pages 4885-4893 | Published online: 06 Oct 2017

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Claudia Arena, Giuseppe Troiano, Khrystyna Zhurakivska, Riccardo Nocini & Lorenzo Lo Muzio. (2019) Stomatitis And Everolimus: A Review Of Current Literature On 8,201 Patients. OncoTargets and Therapy 12, pages 9669-9683.
Read now

Articles from other publishers (3)

Aristotelis Bamias, Roubini Zakopoulou, Kimon Tzannis, Minas Sakellakis, Konstantinos Koutsoukos, Anastasios Kyriazoglou, Aikaterini Panagiotou, Stylianos Armylagos, Konstantinos Rokas, Dimitrios Gotzias, Anna Boulouta, Vassiliki Bozionelou, Konstantinos Stravodimos, Ioannis Varkarakis, Dimitrios Mavroudis & Meletios-Athanasios Dimopoulos. (2022) Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigm. Anti-Cancer Drugs 34:3, pages 413-421.
Crossref
Ruggero Lasala, Fiorenzo Santoleri, Alessia Romagnoli, Felice Musicco, Paolo Abrate & Alberto Costantini. (2021) Randomized clinical trials and real life studies: Comparison of baseline characteristics of patients in oral target therapies for renal cell carcinoma. Journal of Oncology Pharmacy Practice 28:4, pages 870-883.
Crossref
Lajos Géczi, György Bodoky, György Rokszin, Ibolya Fábián & László Torday. (2020) Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma. Pathology & Oncology Research 26:4, pages 2201-2207.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.